Get startedLog in
    Picture of Roche Holding AG logo

    ROP — Roche Holding AG News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: European Commission Approves Roche’s Susvimo For Treatment Of Neovascular Age-Related Macular Degeneration

    Picture of Roche Holding AG logoRoche Holding AG
    21/09/2026 16:52
    BRIEF-European Commission Approves Roche’s Susvimo For Treatment Of Neovascular Age-Related Macular Degeneration
    Sept 21 (Reuters) - ROCHE HOLDING AG ROPC.S:
    • EUROPEAN COMMISSION APPROVES ROCHE’S SUSVIMO® FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
    • PHASE III ARCHWAY STUDY SHOWS SUSVIMO MAINTAINS VISION EQUIVALENT TO MONTHLY INJECTIONS
    Source text: ID:nGNE2CVCGc
    Further company coverage: ROPC.S

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))

    Recent news on Roche Holding AG

    See all news